FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2758053670> ?p ?o ?g. }

• W2758053670 endingPage "108.e2" @default.
• W2758053670 startingPage "96" @default.
• W2758053670 abstract "Study objective Little is known about the use of ibutilide for cardioversion in atrial fibrillation and flutter outside of clinical trials. We seek to describe patient characteristics, ibutilide administration patterns, cardioversion rates, and adverse outcomes in the community emergency department (ED) setting. We also evaluate potential predictors of cardioversion success. Methods Using a retrospective cohort of adults who received ibutilide in 21 community EDs between January 2009 and June 2015, we gathered demographic and clinical variables from electronic health records and structured manual chart review. We calculated rates of cardioversion and frequency of ventricular tachycardia within 4 hours and estimated adjusted odds ratios (aOR) in a multivariate regression model for potential predictors of cardioversion. Results Among 361 patients, the median age was 61 years (interquartile range 53 to 71 years) and most had recent-onset atrial fibrillation and flutter (98.1%). Five percent of the cohort had a history of heart failure. The initial QTc interval was prolonged (>480 ms) in 29.4% of patients, and 3.1% were hypokalemic (<3.5 mEq/L). The mean ibutilide dose was 1.5 mg (SD 0.5 mg) and the rate of ibutilide-related cardioversion within 4 hours was 54.8% (95% confidence interval [CI] 49.6% to 60.1%), 50.5% for atrial fibrillation and 75.0% for atrial flutter. Two patients experienced ventricular tachycardia (0.6%), both during their second ibutilide infusion. Age (in decades) (aOR 1.3; 95% CI 1.1 to 1.5), atrial flutter (versus atrial fibrillation) (aOR 2.7; 95% CI 1.4 to 5.1), and no history of atrial fibrillation and flutter (aOR 2.0; 95% CI 1.2 to 3.1) were associated with cardioversion. Conclusion The effectiveness and safety of ibutilide in this community ED setting were consistent with clinical trial results despite less stringent patient selection criteria. Little is known about the use of ibutilide for cardioversion in atrial fibrillation and flutter outside of clinical trials. We seek to describe patient characteristics, ibutilide administration patterns, cardioversion rates, and adverse outcomes in the community emergency department (ED) setting. We also evaluate potential predictors of cardioversion success. Using a retrospective cohort of adults who received ibutilide in 21 community EDs between January 2009 and June 2015, we gathered demographic and clinical variables from electronic health records and structured manual chart review. We calculated rates of cardioversion and frequency of ventricular tachycardia within 4 hours and estimated adjusted odds ratios (aOR) in a multivariate regression model for potential predictors of cardioversion. Among 361 patients, the median age was 61 years (interquartile range 53 to 71 years) and most had recent-onset atrial fibrillation and flutter (98.1%). Five percent of the cohort had a history of heart failure. The initial QTc interval was prolonged (>480 ms) in 29.4% of patients, and 3.1% were hypokalemic (<3.5 mEq/L). The mean ibutilide dose was 1.5 mg (SD 0.5 mg) and the rate of ibutilide-related cardioversion within 4 hours was 54.8% (95% confidence interval [CI] 49.6% to 60.1%), 50.5% for atrial fibrillation and 75.0% for atrial flutter. Two patients experienced ventricular tachycardia (0.6%), both during their second ibutilide infusion. Age (in decades) (aOR 1.3; 95% CI 1.1 to 1.5), atrial flutter (versus atrial fibrillation) (aOR 2.7; 95% CI 1.4 to 5.1), and no history of atrial fibrillation and flutter (aOR 2.0; 95% CI 1.2 to 3.1) were associated with cardioversion. The effectiveness and safety of ibutilide in this community ED setting were consistent with clinical trial results despite less stringent patient selection criteria." @default.
• W2758053670 created "2017-10-06" @default.
• W2758053670 creator A5001157620 @default.
• W2758053670 creator A5006836050 @default.
• W2758053670 creator A5031901463 @default.
• W2758053670 creator A5041273039 @default.
• W2758053670 creator A5046342765 @default.
• W2758053670 creator A5051650514 @default.
• W2758053670 creator A5070480782 @default.
• W2758053670 creator A5086611319 @default.
• W2758053670 date "2018-01-01" @default.
• W2758053670 modified "2023-09-27" @default.
• W2758053670 title "Ibutilide Effectiveness and Safety in the Cardioversion of Atrial Fibrillation and Flutter in the Community Emergency Department" @default.
• W2758053670 cites W1428777146 @default.
• W2758053670 cites W1551265431 @default.
• W2758053670 cites W1557874646 @default.
• W2758053670 cites W1670463745 @default.
• W2758053670 cites W1739971684 @default.
• W2758053670 cites W1808975055 @default.
• W2758053670 cites W1964127609 @default.
• W2758053670 cites W1966064887 @default.
• W2758053670 cites W1970252226 @default.
• W2758053670 cites W1973530633 @default.
• W2758053670 cites W1980159897 @default.
• W2758053670 cites W1988681636 @default.
• W2758053670 cites W1990630798 @default.
• W2758053670 cites W2008898492 @default.
• W2758053670 cites W2013863450 @default.
• W2758053670 cites W2014041843 @default.
• W2758053670 cites W2016484297 @default.
• W2758053670 cites W2021320779 @default.
• W2758053670 cites W2031550954 @default.
• W2758053670 cites W2033693131 @default.
• W2758053670 cites W2035710068 @default.
• W2758053670 cites W2051923490 @default.
• W2758053670 cites W2054303252 @default.
• W2758053670 cites W2059869646 @default.
• W2758053670 cites W2061978896 @default.
• W2758053670 cites W2063496978 @default.
• W2758053670 cites W2066805338 @default.
• W2758053670 cites W2086462421 @default.
• W2758053670 cites W2088808609 @default.
• W2758053670 cites W2093427810 @default.
• W2758053670 cites W2096338776 @default.
• W2758053670 cites W2108174487 @default.
• W2758053670 cites W2108753291 @default.
• W2758053670 cites W2117709805 @default.
• W2758053670 cites W2121394112 @default.
• W2758053670 cites W2129291556 @default.
• W2758053670 cites W2130780862 @default.
• W2758053670 cites W2131080057 @default.
• W2758053670 cites W2141289730 @default.
• W2758053670 cites W2143440359 @default.
• W2758053670 cites W2153168564 @default.
• W2758053670 cites W2154025234 @default.
• W2758053670 cites W2154328340 @default.
• W2758053670 cites W2162330026 @default.
• W2758053670 cites W2164131160 @default.
• W2758053670 cites W2164861810 @default.
• W2758053670 cites W2319006749 @default.
• W2758053670 cites W2327912473 @default.
• W2758053670 cites W2513439676 @default.
• W2758053670 cites W2531283242 @default.
• W2758053670 cites W2531787552 @default.
• W2758053670 cites W2554107298 @default.
• W2758053670 cites W2575409261 @default.
• W2758053670 cites W3030533492 @default.
• W2758053670 cites W34600178 @default.
• W2758053670 cites W4252866508 @default.
• W2758053670 doi "https://doi.org/10.1016/j.annemergmed.2017.07.481" @default.
• W2758053670 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28969929" @default.
• W2758053670 hasPublicationYear "2018" @default.
• W2758053670 type Work @default.
• W2758053670 sameAs 2758053670 @default.
• W2758053670 citedByCount "20" @default.
• W2758053670 countsByYear W27580536702018 @default.
• W2758053670 countsByYear W27580536702019 @default.
• W2758053670 countsByYear W27580536702020 @default.
• W2758053670 countsByYear W27580536702021 @default.
• W2758053670 countsByYear W27580536702022 @default.
• W2758053670 countsByYear W27580536702023 @default.
• W2758053670 crossrefType "journal-article" @default.
• W2758053670 hasAuthorship W2758053670A5001157620 @default.
• W2758053670 hasAuthorship W2758053670A5006836050 @default.
• W2758053670 hasAuthorship W2758053670A5031901463 @default.
• W2758053670 hasAuthorship W2758053670A5041273039 @default.
• W2758053670 hasAuthorship W2758053670A5046342765 @default.
• W2758053670 hasAuthorship W2758053670A5051650514 @default.
• W2758053670 hasAuthorship W2758053670A5070480782 @default.
• W2758053670 hasAuthorship W2758053670A5086611319 @default.
• W2758053670 hasConcept C118552586 @default.
• W2758053670 hasConcept C119060515 @default.
• W2758053670 hasConcept C126322002 @default.
• W2758053670 hasConcept C156957248 @default.
• W2758053670 hasConcept C164705383 @default.
• W2758053670 hasConcept C2775914520 @default.
• W2758053670 hasConcept C2777289489 @default.
• W2758053670 hasConcept C2778094803 @default.

• next